Themis Medicare Ltd Q2 FY25 (Half-Year FY25): From Hospital Beds to Red Ink – The Curious Case of ₹17,557 mn Revenue, ₹1,783 mn Loss, and Pharma’s Comedy of Errors
1. At a Glance
Ladies and gentlemen, welcome to Themis Medicare Ltd’s Half-Year FY25 circus, where the star performer isn’t a new drug but the company’s impressive ability to turn operating profits into red ink faster than a doctor writing illegible prescriptions. The stock now trades at ₹108 – that’s nearly 65% down from its 52-week high of ₹304. Market cap stands at a modest ₹993 crore, which is basically “paracetamol” money compared to the big pharma whales like Sun Pharma or Dr. Reddy’s.
Let’s talk painkillers—because this balance sheet hurts. The company’s half-year consolidated revenue sits at ₹17,557.18 lakh (₹175.57 crore), but instead of prescribing profits, it delivered a loss of ₹1,783.53 lakh. ROE is a tired 7.65%, and the stock P/E… well, negative EPS means there’s no P/E to calculate, so let’s just say “Prescription Error.”
Debt of ₹95.6 crore on the books and an interest coverage ratio of -1.58 don’t exactly scream financial fitness. Still, promoters hold a confident 67.15% stake, probably hoping their API business can soon stop behaving like an expired antibiotic.
2. Introduction
Back in 1969, when Bollywood heroes still wore bell-bottoms and Amul butter was the height of brand loyalty, Themis Medicare Ltd was incorporated to manufacture pharmaceutical formulations and APIs. Fast-forward fifty-six years, and Themis finds itself fighting multiple ailments: falling margins, negative operating profits, and a shareholder base that’s developing hypertension.
The company is a curious mix—half pharma innovator, half hospital supplier, and one-third storyteller (judging by how every quarter features a new “turnaround” narrative). It manufactures everything from antiseptics and anti-TB drugs to cholesterol and pain management products. But despite a product portfolio of 240+ formulations and six APIs, the balance sheet lately looks like a patient who skipped all their follow-up appointments.
While peers like Sun Pharma and Lupin are writing billion-dollar scripts in the U.S. generics market, Themis is fighting a desi-level soap opera of fluctuating sales, negative margins, and boardroom drama—complete with merger proposals, withdrawals, and tax demands.
Yet, in true pharma style, hope lives on. The company is betting big on hospital expansion, new markets in Latin America, and an ambitious entry into regulated markets. Whether this prescription cures the ailment or worsens the condition—well, that’s where the fun begins.
3. Business Model – WTF Do They Even Do?
Let’s simplify. Themis Medicare is a pharma company that does a bit of everything—kind of like your neighbourhood chemist who also offers blood pressure advice and free gossip.
1. Hospital Business: This is the ICU of Themis—literally. The Critical Care and Intensive Care divisions supply anaesthesia, pain management, and anti-infective products to hospitals across India. This segment accounts for about 38% of revenue. They’ve even installed ~70 anaesthesia pumps this year, possibly hoping hospitals will prescribe them more purchases instead of antibiotics.
2. Trade Business: Pharma, Ortho, and Gynecology divisions—basically, they sell medicines that doctors can’t pronounce but still prescribe. Around 20% of their revenue stems from this retail-focused business.
3. API Business: This is the manufacturing backbone. With two major API plants (Hyderabad and Vapi), they produce synthetic and biotech APIs like Artemisinin derivatives—used in anti-malarials. This contributes ~42% of total revenue.
Their in-house R&D (recognized by the Ministry of Science & Technology) has rolled out 240+ formulations. In short, Themis is like the “Jack of All Molecules.” Whether it’s anti-TB, anti-malarial, or anti-loss, they’re trying to formulate it.
And there it is—the pharma version of a “before and after” ad, except it’s in reverse. From ₹117 crore revenue last year to ₹78 crore this year. PAT went from +₹14.29 crore to -₹3.62 crore.
Quarterly EPS at ₹-0.39 means if you bought this share expecting dividends, you’re basically donating to medical research.
The operating profit margin collapsed from 14.64% to -3.97%. In finance terms, that’s like an injection missing the vein—it stings, but the damage is deeper than it looks.
